Search Results

Biora Therapeutics, Inc today announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600.

Voyager Therapeutics, Inc. today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer’s disease.

Gain Therapeutics, Inc. announces positive results from the single ascending dose (SAD) part of its Phase 1 study.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of the single-ascending dose (SAD) cohorts for its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023.

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma”) today announces that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.”

AliveGen USA Inc. is delighted to announce the successful completion of its Phase 1b multiple-ascending dose (MAD) clinical trial for ALG-801.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule RNA splicing modifiers, today announced that the Phase 1 multiple ascending dose (MAD) portion of its Phase 1 clinical study has now begun in Australia for the company’s SKY-0515 small molecule candidate targeting Huntington’s disease (HD).

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”) announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287, Gain’s lead drug candidate for the treatment of GBA1 Parkinson’s disease.